Get started
Author

Amy Hammell

Observed name: A Hammell
ORCID: 0009-0002-3680-3836
Observed ORCID: 0009-0002-3680-3836
OpenAlex ID: A5111856781
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
2017 · Ting Jin, Hugo Lavoie, et al. · Nature Communications · 102
PDF
Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.
2022 · Heinz-Josef Lenz, Aparna Raj Parikh, et al. · Journal of Clinical Oncology · 61
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
2022 · John Hilton, Mihaela Cristea, et al. · Cancers · 44
PDF
Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
2011 · Tai W. Wong, Francis Y. Lee, et al. · Clinical Cancer Research · 24
Abstract CT235: REPLOT Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition
2025 · Jason A. Mouabbi, Amy Hammell, et al. · Cancer Research · 3
Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
2022 · Marwan Fakih, Kanwal Pratap Singh Raghav, et al. · Journal of Clinical Oncology · 3
Improving Anti–CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies
2026 · Amy Jhatakia, Xin Sun, et al. · Clinical Cancer Research · 2
PDF
592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results
2022 · Claire Friedman, Richard Carvajal, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
Supplementary Data from Improving Anti–CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies
2026 · Amy Jhatakia, Xin Sun, et al.
Data from Improving Anti–CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies
2026 · Amy Jhatakia, Xin Sun, et al.
Improving anti-CTLA-4 therapies through peptide masking and Fc non-fucosylation: preclinical characterization of three novel antibodies
2025 · A Jhatakia, A Jhatakia, et al. · immuneACCESS
Supplementary Figures 1-6 from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
2023 · Tai W. Wong, Francis Y. Lee, et al.
Supplementary Tables 1-3, Figure Legends 1-6 from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
2023 · Tai W. Wong, Francis Y. Lee, et al.
PDF
Data from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
2023 · Tai W. Wong, Francis Y. Lee, et al.
Data from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
2023 · Tai W. Wong, Francis Y. Lee, et al.
Supplementary Figures 1-6 from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
2023 · Tai W. Wong, Francis Y. Lee, et al.
PDF
Supplementary Tables 1-3, Figure Legends 1-6 from Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
2023 · Tai W. Wong, Francis Y. Lee, et al.
Works count: 17
Citation count: 241
H-index: 4
I10-index: 4
Year
Topic
Type